The immuno-oncology drug developer, which counts numerous pharmaceutical firms among its investors, has filed for a $100m offering in the US.
Germany-based cancer immunotherapy developer BioNTech has filed for a $100m initial public offering on the Nasdaq Global Select Market that would allow pharmaceutical companies Sanofi and Pfizer to exit.
BioNTech, a spinout from Johannes Gutenberg University Mainz, is working on the development of individualised immunotherapies to treat cancer and potentially other diseases.
Part of the IPO proceeds will fund clinical trials for three drug candidates respectively addressing advanced melanoma, breast cancer and HPV-related head and neck cancer.
Additional funds…
